Ocugen officer plans $589K sale of 526K shares

Ocugen, Inc. (OCGN) received notice that officer Shankar Musunuri plans to sell up to 525,991 shares of Ocugen common stock under Rule 144 through Merrill Lynch.

Available on EDGAR 09/09/2026 - 04:31 PM EDT Accepted by SEC EDGAR 09/09/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ocugen, Inc. (OCGN) received notice that officer Shankar Musunuri plans to sell up to 525,991 shares of Ocugen common stock under Rule 144 through Merrill Lynch. The shares derive from multiple equity compensation grants between February 2014 and January 2026 and have an aggregate market value of $589,741.11.

Key Figures

Shares to be sold: 525,991 shares Aggregate market value: $589,741.11 Grant-based share amount (01/03/2026): 349,621 shares +5 more

8 metrics

Shares to be sold 525,991 shares Ocugen common stock planned for sale under Rule 144 by Shankar Musunuri

Aggregate market value $589,741.11 Value reported for 525,991 Ocugen common shares held at Merrill Lynch

Grant-based share amount (01/03/2026) 349,621 shares Equity compensation grant from issuer dated January 3, 2026

Grant-based share amount (01/03/2023) 77,636 shares Equity compensation grant from issuer dated January 3, 2023

Grant-based share amount (01/03/2025) 41,470 shares Equity compensation grant from issuer dated January 3, 2025

Grant-based share amount (02/10/2014) 49,165 shares Equity compensation grant from issuer dated February 10, 2014

Grant-based share amount (11/17/2016) 8,099 shares Equity compensation grant from issuer dated November 17, 2016

Date of notice September 9, 2026 Date associated with the Rule 144 notice for Ocugen shares

Key Terms

Rule 144, Equity Compensation, Securities To Be Sold, Date of Notice

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Equity Compensation financial

"Common | 01/03/2026 | Equity Compensation | Issuer"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

Securities To Be Sold financial

"144: Securities To Be Sold"

Date of Notice regulatory

"Date of Notice | 09/09/2026 06/05/2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ocugen (OCGN) disclose about Shankar Musunuri in this Rule 144 notice?

The notice states that officer Shankar Musunuri plans to sell up to 525,991 shares of Ocugen common stock under Rule 144, with the shares held at Merrill Lynch and obtained through equity compensation grants.

How many OCGN shares are planned to be sold under this Rule 144 filing?

The planned sale covers 525,991 shares of Ocugen common stock, with an aggregate market value of $589,741.11 as reported. These shares come from several equity compensation awards granted between 2014 and 2026.

What is the reported market value of the OCGN shares in the Rule 144 notice?

The notice reports an aggregate market value of $589,741.11 for the 525,991 Ocugen common shares held for potential sale through Merrill Lynch on NASDAQ.

How were the OCGN shares to be sold by Shankar Musunuri originally acquired?

All the Ocugen shares listed for sale were acquired through equity compensation from the issuer on specific grant dates, including January 3, 2026, January 3, 2025, January 3, 2023, February 10, 2014, and November 17, 2016.

When was the Rule 144 notice for OCGN dated?

The notice is dated September 9, 2026, with an additional date of June 5, 2026 also shown. It relates to the planned sale of 525,991 shares of Ocugen common stock under Rule 144.

Through which broker and market are the OCGN shares associated with this Rule 144 notice?

The shares are held at Merrill Lynch, located at 4 Penn Center in Philadelphia, and relate to Ocugen common stock listed on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001791820
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ocugen, Inc.
SEC File Number	001-36751
Address of Issuer	11 Great Valley Parkway Malvern PENNSYLVANIA 19355
Phone	4843284701
Name of Person for Whose Account the Securities are To Be Sold	Shankar Musunuri
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 4 Penn Center - 1600 JFK Blvd Philadelphia PA 19103	525991	589741.11	339110401	09/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/03/2026	Equity Compensation	Issuer			349621	01/03/2026	Equity Compensation
Common	01/03/2023	Equity Compensation	Issuer			77636	01/03/2023	Equity Compensation
Common	01/03/2025	Equity Compensation	Issuer			41470	01/03/2025	Equity Compensation
Common	02/10/2014	Equity Compensation	Issuer			49165	02/10/2014	Equity Compensation
Common	11/17/2016	Equity Compensation	Issuer			8099	11/17/2016	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Shares sold via Shankar Musunuri, Individually and via KVM holdings
Date of Notice	09/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/05/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Shankar Musunuri
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)